Thymus Factor and Immunology
THYMUS FACTOR supplement is an innovative formula based on a complex composition developed based on the latest scientific and technological solutions, combined with knowledge gained through years of experience. The manufacturer of this supplement is also responsible for the TFX® drug, which contains biologically active peptides isolated from carefully selected thymus glands, meeting high medical standards in terms of quality and safety.
Calf thymus extract has an immunomodulating effect, complementing the functions of the thymus gland, which is essential for the proper functioning of the immune system. Our thymus-based preparations are the result of Polish biotechnological innovation and represent 35 years of clinical research on thymus-derived preparations.
Selected Publications on Thymic Hormones
The role of thymic hormones in the treatment of COVID-19
A group of Chinese researchers retrospectively analyzed the clinical status of patients infected with the SARS-CoV-2 virus. In a study published in Clinical Infectious Diseases, they discovered a significant difference in mortality rates between patients treated with Thymosin Alpha 1 (Tα1) and those not treated with it, with mortality rates of 11% and 30%, respectively.
Calf thymus hormones inhibit the growth of colon tumors (May 2022)
An article published in May 2022 in the journal Frontiers in Pharmacology describes the impact of calf thymus polypeptides on regulating immune functions dependent on gut microbiota. In the mice studied, there was an increase in proteins and cytokines associated with immunity as well as an increase in T lymphocytes, effectively slowing the growth of colon tumors.
Melanoma treatment using thymosin – long-term impact on patients.
An article published in the journal Expert Opinion on Biological Therapy analyzed the overall survival time after treatment for metastatic melanoma. Patients were treated at various periods between June 2004 and August 2011, and their status was reported as of July 1, 2017. Italian researchers used two types of therapies:
Analysis of the effects of thymic hormones on the treatment of malignant pleural effusion
An article published in International Immunopharmacology presented the work of Chinese researchers who analyzed 34 reports on the treatment of malignant pleural effusion using thymic hormones. They found that patients who received thymosins combined with oxaliplatin had better treatment outcomes.
Long-term impact of Thymosin Alpha 1 as an immunomodulatory therapy on the treatment of lung cancer patients (December 2021)
group of Chinese researchers conducted a retrospective analysis of the clinical status of patients infected with the SARS-CoV-2 virus. In a study published in Clinical Infectious Diseases, they discovered a significant difference in mortality rates between patients treated with Thymosin Alpha 1 (Tα1) and those who were not treated with it, showing mortality rates of 11% and 30%, respectively.
Among COVID-19 patients admitted to two hospitals in Wuhan, China, between December 2019 and March 2020, 76 severe cases were tracked, all of whom had been hospitalized for at least 10 days.